Connective tissue disease subtype by treatment group
| n (%) | Combination therapy (n=103) | Monotherapy pooled (n=84) | Ambrisentan monotherapy (n=44) | Tadalafil monotherapy (n=40) | Total (N=187) |
|---|---|---|---|---|---|
| Limited cutaneous systemic sclerosis | 52 (50) | 30 (36) | 17 (39) | 13 (33) | 82 (44) |
| Diffuse cutaneous systemic sclerosis | 19 (18) | 17 (20) | 6 (14) | 11 (28) | 36 (19) |
| Mixed connective tissue disease | 11 (11) | 12 (14) | 3 (7) | 9 (23) | 23 (12) |
| Systemic lupus erythematosus | 11 (11) | 6 (7) | 5 (11) | 1 (3) | 17 (9) |
| Overlap syndrome | 2 (2) | 1 (1) | 0 | 1 (3) | 3 (2) |
| Other | 8 (8) | 18 (21) | 13 (30) | 5 (13) | 26 (14) |